Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Maze Therapeutics Inc's Competitiveness

Name: Maze Therapeutics Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Maze Therapeutics Inc (MAZE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/MAZE/competitors                    

                        https://api.csimarket.com/api/v1/companies/MAZE/relationships                    

                        https://api.csimarket.com/api/v1/companies/MAZE/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Maze Therapeutics Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Maze Therapeutics Inc	-	-	-	Yes
High-Confidence Competitors (1)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

MAZE Stock Performance relative to its Competitors

MAZE Competitors (weighted) Percent change over the selected range

Maze Therapeutics Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 1)

Similar-Size
(7 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Maze Therapeutics Inc	5.20 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (1)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Maze Therapeutics Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

MAZE Stock Performance relative to High-Confidence Competitors

MAZE High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

MAZE Stock Performance relative to Similar-Size Competitors

MAZE Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Maze Therapeutics Inc's Comment on Competition and Industry Peers

The company operates in the pharmaceutical and biotechnology industry, which is characterized by rapid technological advancements and intense competition. Its competitors include major pharmaceutical and biotechnology companies, academic institutions, government agencies, and private and public research institutions. Competitors may obtain regulatory approval earlier or develop more advanced therapies or technologies, potentially impacting the company's business and financial condition. The company also faces challenges in protecting intellectual property rights and may incur costs related to litigation for infringement. Additionally, its therapeutic candidates may compete with existing and future approved therapies for the same indications.

Competitor data is not yet available for Maze Therapeutics Inc.

Maze Therapeutics Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Entrada Therapeutics Inc	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Maze Therapeutics Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.